Drug Effects on Mood and Behavior - Expectancy

NCT ID: NCT07061886

Last Updated: 2025-07-11

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-26
• Study Completion Date: 2026-06-05

Brief Summary

This study will examine the effects of a single low dose of the 5HT2A agonist LSD (Lysergic Acid Diethylamide) (13 µg) or placebo in individuals who are or are not explicitly told what drug they will receive. Although it is known that expectancies strongly influence subjective responses to most drugs, no studies have examined expectancies on response to a very low dose of LSD. This is especially important in the context of 'microdosing' of drugs. People who practice microdosing typically do so with strong expectations of positive effects, making it difficult to determine whether there is a pharmacological effect. To minimize expectancies in the laboratory, participants are usually not told exactly what drug they will receive (i.e., double-blind), but given a range of possibilities. In the present study, the study team will test half the subjects under single-blind conditions, where the participants (but not the research assistant) will know exactly what they are receiving. Other subjects will receive the usual instructions. Healthy volunteers will receive either a marginally detectable dose of LSD (13 micrograms) or placebo, under conditions where they i) know for sure what drug they are receiving or ii) where the identity of the drug is uncertain. Four groups of subjects (N=12 each) will attend single 4-hour laboratory session. The study team will examine subjective and behavioral responses to the drug in each of four conditions (Known-Drug; Known-Placebo; Uncertain-Drug; Uncertain-Placebo).

Detailed Description

Expectancies are known to influence responses to psychoactive drugs. The study team and others have shown previously, using a balanced placebo design, that expectancies influence responses to alcohol, nicotine, caffeine, stimulant drugs, and cannabinoids. In these studies subjects are randomly assigned to one of four conditions: Expect the drug and get the drug; Expect the drug and get placebo; Expect placebo and get the drug; Expect placebo and get placebo. This allows researchers to separate pharmacological effects from expectancy effects.

Recently there has been much discussion about the role of expectancies specifically in responses to psychedelic drugs. Expectancies are especially important in the use of very low doses, referred to as 'microdoses'. These doses are typically at or below the threshold of detectability, but users take them with strong prior beliefs that the drugs improve mood and cognition. The beneficial effects have been difficult to demonstrate under laboratory conditions, perhaps because in the laboratory the drugs are administered without the explicit expectation of benefits, and the administration of the drugs is to some extent blinded. The present study is designed to separate the pharmacological effects of a low dose of LSD from effects that are influenced by expectancies.

Conditions

LSD

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: TRIPLE

Study Groups

LSD (13 micrograms), Identity of substance known

LSD tartrate in tasteless solution (0.13 mL). Subjects will receive LSD, and they (but not the research assistant) will be told the identity of the drug.

Group Type: EXPERIMENTAL

LSD

Intervention Type: DRUG

The serotonin 2A receptor agonist LSD

LSD (13 micrograms), Identity uncertain

LSD tartrate in tasteless solution (0.13 mL). Subjects will be told they might receive a stimulant, sedative, low dose of hallucinogen, or placebo, and will receive LSD.

Group Type: ACTIVE_COMPARATOR

LSD

Intervention Type: DRUG

The serotonin 2A receptor agonist LSD

Placebo, Identity of substance known

Distilled water (0.13 mL). Subjects will receive placebo, and they (but not the research assistant) will be told the identity of the drug.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Distilled water (0.26 mL)

Placebo, Identity uncertain

Distilled water (0.13 mL). Subjects will be told they might receive a stimulant, sedative, low dose of hallucinogen, or placebo, and will receive placebo.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Distilled water (0.26 mL)

Interventions

LSD

The serotonin 2A receptor agonist LSD

Intervention Type: DRUG

Placebo

Distilled water (0.26 mL)

Intervention Type: DRUG

Other Intervention Names

Lysergic acid diethylamide

Eligibility Criteria

Inclusion Criteria

• English Fluency
• High school education or higher
• BMI between 19-30 kg/m2

Exclusion Criteria

• Individuals with a medical condition contraindicating study participation as determined by the study physician (e.g., liver disease, abnormal EKG, liver or cardiovascular disease)
• High blood pressure (>140/90)
• Current suicidal ideation or suicide attempt in past 12 months
• Past year severe substance use disorder
• Personal or first-degree relative with history of psychosis
• Currently taking any psychiatric medication (for conventional antidepressants must be off for ≥ 2 weeks)
• Active panic disorder
• Severe obsessive-compulsive disorder
• Severe post-traumatic stress disorder
• Women who are pregnant or planning to become pregnant

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role: collaborator

University of Chicago

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hanna Molla

Role: PRINCIPAL_INVESTIGATOR

University of Chicago

Locations

University of Chicago

Chicago, Illinois, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Hanna Molla

Role: CONTACT

hmolla@uchicago.edu

7737023560

Facility Contacts

Hanna Molla

Role: primary

hmolla@uchicago.edu

References

Aron, A., Melinat, E., Aron, E. N., Vallone, R. D., & Bator, R. J. (1997). The Experimental Generation of Interpersonal Closeness: A Procedure and Some Preliminary Findings. Personality and Social Psychology Bulletin, 23(4), 363-377. https://doi.org/10.1177/0146167297234003

Reference Type: BACKGROUND

Beck, A. T., Steer, R. A., & Brown, G. (1996). Beck Depression Inventory-II (BDI-II). In APA PsycTests

Reference Type: BACKGROUND

Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Biol Psychiatry. 2019 Nov 15;86(10):792-800. doi: 10.1016/j.biopsych.2019.05.019. Epub 2019 Jun 3.

Reference Type: BACKGROUND

PMID: 31331617 (View on PubMed)

de Wit H, Molla HM, Bershad A, Bremmer M, Lee R. Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study. Addict Biol. 2022 Mar;27(2):e13143. doi: 10.1111/adb.13143. Epub 2022 Feb 1.

Reference Type: BACKGROUND

PMID: 35106880 (View on PubMed)

Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 1998 Jul;31 Suppl 2:80-4. doi: 10.1055/s-2007-979351.

Reference Type: BACKGROUND

PMID: 9754838 (View on PubMed)

Fadiman, J and Gruber, J (2025) Microdosing for Health, Healing, and Enhanced Performance, St Martins Group

Reference Type: BACKGROUND

Fischman MW, Foltin RW. Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict. 1991 Dec;86(12):1563-70. doi: 10.1111/j.1360-0443.1991.tb01749.x.

Reference Type: BACKGROUND

PMID: 1786488 (View on PubMed)

Güth, W, RSchmittberger, B Schwarze (1982) An experimental analysis of ultimatum bargaining. Journal of Economic Behavior & Organization, Volume 3, 367-388

Reference Type: BACKGROUND

Hammami MM, Al-Gaai EA, Alvi S, Hammami MB. Interaction between drug and placebo effects: a cross-over balanced placebo design trial. Trials. 2010 Nov 19;11:110. doi: 10.1186/1745-6215-11-110.

Reference Type: BACKGROUND

PMID: 21092089 (View on PubMed)

Lyvers MF, Maltzman I. The balanced placebo design: effects of alcohol and beverage instructions cannot be independently assessed. Int J Addict. 1991 Sep;26(9):963-72. doi: 10.3109/10826089109058933.

Reference Type: BACKGROUND

PMID: 1743824 (View on PubMed)

Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):245-58. doi: 10.1002/cpt1971122part1245. No abstract available.

Reference Type: BACKGROUND

PMID: 5554941 (View on PubMed)

McNair, D., Lorr, M., Droppleman, L., (1971). POMS, Profile of Mood States. E. a. I. T. Services.

Reference Type: BACKGROUND

Metrik J, Kahler CW, Reynolds B, McGeary JE, Monti PM, Haney M, de Wit H, Rohsenow DJ. Balanced placebo design with marijuana: pharmacological and expectancy effects on impulsivity and risk taking. Psychopharmacology (Berl). 2012 Oct;223(4):489-99. doi: 10.1007/s00213-012-2740-y. Epub 2012 May 16.

Reference Type: BACKGROUND

PMID: 22588253 (View on PubMed)

Molla H, Lee R, Tare I, de Wit H. Greater subjective effects of a low dose of LSD in participants with depressed mood. Neuropsychopharmacology. 2024 Apr;49(5):774-781. doi: 10.1038/s41386-023-01772-4. Epub 2023 Dec 2.

Reference Type: BACKGROUND

PMID: 38042914 (View on PubMed)

Murphy RJ, Muthukumaraswamy S, de Wit H. Microdosing Psychedelics: Current Evidence From Controlled Studies. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 May;9(5):500-511. doi: 10.1016/j.bpsc.2024.01.002. Epub 2024 Jan 26.

Reference Type: BACKGROUND

PMID: 38280630 (View on PubMed)

Palmer AM, Brandon TH. Nicotine or expectancies? Using the balanced-placebo design to test immediate outcomes of vaping. Addict Behav. 2019 Oct;97:90-96. doi: 10.1016/j.addbeh.2019.04.026. Epub 2019 Apr 26.

Reference Type: BACKGROUND

PMID: 31174168 (View on PubMed)

Skopp G, Potsch L, Mattern R, Aderjan R. Short-term stability of lysergic acid diethylamide (LSD), N-desmethyl-LSD, and 2-oxo-3-hydroxy-LSD in urine, assessed by liquid chromatography-tandem mass spectrometry. Clin Chem. 2002 Sep;48(9):1615-8. No abstract available.

Reference Type: BACKGROUND

PMID: 12194952 (View on PubMed)

Szigeti B, Heifets BD. Expectancy Effects in Psychedelic Trials. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 May;9(5):512-521. doi: 10.1016/j.bpsc.2024.02.004. Epub 2024 Feb 20.

Reference Type: BACKGROUND

PMID: 38387698 (View on PubMed)

Related Links

http://doi.org/10.1016/j.biopsych.2019.05.019

Bershad et al., 2019

http://doi.org/10.1055/s-2007-979351

Dittrich, 1998

http://doi.org/10.1186/1745-6215-11-110

Hammami et al., 2010

http://doi.org/10.1007/s00213-012-2740-y

Metrik et al., 2012

http://doi.org/10.1038/s41386-023-01772-4

Molla et al., 2024

http://doi.org/10.1016/j.bpsc.2024.01.002

Murphy et al., 2024

http://doi.org/10.1016/j.addbeh.2019.04.026

Palmer et al., 2019

http://doi.org/10.1016/j.bpsc.2024.02.004

Szigeti \& Heifets, 2024

Other Identifiers

5R01DA002812-35

Identifier Type: NIH

Identifier Source: secondary_id

View Link

IRB25-0658

Identifier Type: -

Identifier Source: org_study_id